NCT01582191 2025-10-27
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
10 trialsNCT01586624 2021-10-07
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Cancer Research UK
Phase 1 Completed
NCT02239952 2020-10-08
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
Amsterdam UMC, location VUmc
Phase NA Unknown
NCT00272350 2019-12-05
ZD6474 to Treat Advanced Brain Cancer in Patients
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00923247 2018-11-29
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00500292 2018-01-25
A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
Sanofi
Phase 2 Completed
NCT00508001 2016-10-10
Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
Sanofi
Phase 2 Completed
NCT00503711 2016-08-31
Phase I Chinese PK
Sanofi
Phase 1 Completed
NCT01372813 2015-10-23
Vandetanib to Treat Advanced Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02530411 2015-08-21
FURVA
Velindre NHS Trust
Phase 2 Unknown